TSG101 is a candidate tumor suppressor gene whose deletion in NIH3T3 cells leads to spontaneous lung metastases in nude mice. Aberrant transcripts of TSG101 have been identi®ed in 47% of primary breast carcinomas, without evidence of intragenic deletions at the TSG101 locus on 11p15. To investigate the possible role of TSG101 in lung cancer, which often shows 11p allele loss, we performed transcript analysis and mutational analysis of TSG101 in lung cancer cell lines. Reverse transcriptase RT ± PCR and Northern analysis detected a common TSG101 transcript, shortened because of an internal deletion, which was expressed simultaneously with the wild-type transcript in 89% of small cell lung cancer (SCLC) lines. In contrast, the wild-type transcript was expressed alone in normal tissues, primary non-small cell lung cancer (NSCLC) specimens, and the majority of NSCLC cell lines. Sequence of the shortened SCLC transcript was identical to that of the most common aberrant transcript identi®ed in breast cancer, consisting of a deletion of exons 2 ± 4 and part of 1 and 5. Southern analysis of SCLC lines expressing the shortened transcript did not detect any intragenic deletions. Single strand conformational polymorphism (SSCP) analysis and direct sequencing of TSG101 cDNAs also identi®ed no mutations or deletions. These results suggest that TSG101 is not mutated in lung cancer but that aberrant splicing of TSG101 occurs in SCLC.
Introduction
While there are many characteristics which distinguish SCLC from the other major lung cancer cell types, one of the most clinically striking is its early metastatic spread. SCLC is diagnosed in approximately 35 000 new patients per year in the United States (Parker et al., 1996; Devesa et al., 1991) , most of whom are found to have distant metastatic disease at the time of clinical diagnosis (Matthews et al., 1973) . In an eort to ®nd a molecular correlate for the markedly malignant phenotype of SCLC, genetic alterations and abnormal expression patterns of many oncogenes and tumor suppressor genes have been investigated. Multiple chromosomal deletions on 3p, 4q, 5q, 9p, 10q, 13q and 17p as well as DNA over-representations on 3q and 5p have been found in primary tumors and their metastases (Kim et al., 1997; Petersen et al., 1997; Cook et al., 1993) . Several tumor suppressor genes have been found to be altered frequently in SCLC including RB whose protein expression is absent or truncated in the majority of tumors and cell lines and p53 which is mutated in more than 80% of tumors and cell lines (Harbour et al., 1988; Rygaard et al., 1992; D'Amico et al., 1992; Miller et al., 1992) . Many other examples also corroborate the theory of cumulative genetic alterations in the tumorigenesis of SCLC.
The mouse candidate tumor suppressor gene tsg101 was recently discovered by Li and Cohen using a random homozygous knockout approach to detect genes whose functional deletion resulted in cellular transformation; suppression of the tsg101 gene in NIH3T3 cells resulted in tumorigenicity and spontaneous lung metastases in a nude mouse model (Li and Cohen, 1996) . Li and colleagues have subsequently cloned the human homolog, TSG101, and identi®ed abnormal transcripts of this gene in 47% of primary breast carcinomas (Li et al., 1997) . While Li et al. (1997) , using genomic PCR, reported intragenic deletions of TSG101 to account for these abnormal transcripts, subsequent studies using Southern blot analysis have failed to con®rm any TSG101 genomic deletions in a panel of breast cancer cell lines and primary tumors (Steiner et al., 1997; Lee and Feinberg, 1997) .
TSG101 was localized to chromosome 11p15 (Li et al., 1997) , a region frequently lost in several human tumor types including breast cancer (Winqvist et al., 1995; Gudmundsson et al., 1995) and NSCLC (Sundareshan and Augustus, 1996; Fong et al., 1994; Bepler et al., 1994; Izuka et al., 1995) . It has been suggested that the 11p allele loss is associated with disease progression in NSCLC (Fong et al., 1994) . While the normal function of TSG101 is unknown, several structural motifs have been identi®ed including a proline-rich region and a predicted coiled-coil domain nearly identical to that of its murine homolog. The murine coiled-coil domain has been shown to interact with a regulator of cell growth and dierentiation called stathmin (Li and Cohen, 1996; Dipaolo et al., 1996; Marklund et al., 1993) . Stathmin, also known as oncoprotein 18 or metablastin, is an evolutionarily conserved protein which is phosphorylated in response to growth and dierentiation factors (Dipaolo et al., 1996; Marklund et al., 1993) , T-cell activation (Gratiot-Deans et al., 1992) , embryonic development (Doye et al., 1992) and tissue regeneration (Koppel et al., 1993) . Stathmin levels have been reported as elevated in acute leukemias/aggressive lymphomas (Roos et al., 1993) , and neuroblastomas (Hallat et al., 1990) . A recent report has identi®ed homology between TSG101 and a class of dominant-negative regulators of the ubiquitin conjugating enzyme E2, leading to the hypothesis that TSG101 may bind ubiquitin and inhibit cyclin degradation (Koonin and Abagyan, 1997) .
On the basis of the above ®ndings, we questioned whether abnormalities in TSG101 might play a role in the pathogenesis of lung cancer. We analysed a large panel of NSCLC and SCLC cell lines for mutations or alterations in the expression of TSG101. We found no evidence for mutation of TSG101 in lung cancer but report an aberrant transcript found frequently and predominantly in SCLC that is identical to one of the aberrant transcripts previously described in breast cancer.
Results

Transcript analysis of TSG101 in SCLC and NSCLC cell lines
The primer pair S1.1/AS1 was used to amplify base pairs 73 ± 1300 of TSG101 cDNA (GenBank U82130) from 33 NSCLC and 44 SCLC cell line cDNAs. All cDNA preparations were pretested and shown to have ampli®cation of a 1083 bp GAPDH control transcript. The predicted 1228 bp full-length TSG101 PCR product was clearly observed in 75% (33/44) of SCLC and 100% (33/33) of NSCLC cell lines tested. An approximately 330 bp transcript was clearly observed in 39 of 44 SCLC cell lines (89%). In SCLC, the wildtype transcript was the sole transcript in 5/44 cell lines (11%) or the dominant transcript expressed in 3/44 cell lines (7%). The wild-type and 330 bp transcripts were expressed in approximately equal amounts of RT ± PCR products in 22/44 cell lines (50%), and the 330 bp product was the sole or dominant transcript in 14/44 cell lines (32%) (Figure 1 ). In contrast, the wild-type form was the dominant transcript expressed in all of the NSCLC cell lines. In 9/33 NSCLC cell lines, a faint 330 bp band could be detected with prolonged UV exposure of the ethidium bromide stained gel, however this band was clearly 10 ± 50-fold less intense than the wild-type transcript in every case (Figure 1) .
To corroborate the presence of the abnormal TSG101 transcript in SCLC cell lines, an alternate primer pair S1/AS1 was used to amplify bps 65-1300 of TSG101 cDNA from a subset of 16 SCLC cell lines (H82, H146, H187, H209, H345, H378, H524, H526, H889, H1045, H1092, H1926, H2107, H2141, H2171 and DMS 79). The 330 bp abnormal transcript was the dominant product in cell lines H345, H378 and H1092 (Figure 2) . A third minor product ranging in size from roughly 100 ± 200 bp or 600 bp (data not shown) was ampli®ed from cDNA of some cell lines. cDNA from normal lung specimens exhibited only a full-length PCR product while a SCLC line (H187) and a human erythroblastic leukemia line (K562) exhibited both the wild-type and 330 bp products (Figure 3 ). When the primer pair S1/AS1 was used to amplify cDNA from nine head and neck squamous cell carcinoma (HNSCC) cell lines, only the full-length PCR product was observed, except in one HNSCC cell line (Tr146) in which a faint smaller PCR product was seen (data not shown). To exclude the possibility of nonspeci®c PCR products and to produce high quality DNA for further sequence analysis, hemi-nested PCR was utilized. The weak abnormal PCR products (100 ± 200 bp and 600 bp) derived from primer pair S1/AS1 were excised and puri®ed from agarose gel and then ampli®ed using primer pair S1.1/AS1, where S1.1 was an internal primer overlapping S1 by ten bases. This method was able to amplify the 100 ± 200 bp products suciently to allow sequence analysis, but was unable to amplify the 600 bp product, suggesting it to have been a nonspeci®c PCR product.
Screening for mutations and sequence analysis of TSG101 RT ± PCR products
The full-length and the shortened TSG101 cDNA products from the 16 SCLC cell lines were sequenced separately. No mutation or sequence variation was In all SCLC cell lines, DNA sequencing of RT ± PCR products showed that the major aberrant product (330 bp) displayed homology with the published TSG101 sequence. However, this cDNA exhibited a deletion from base pairs 154 ± 1054 encompassing exons 2, 3, 4 and parts of exons 1 and 5 ( Figure 4 ). This shortened variant was identical to one described in breast cancer (Li et al., 1997) . Three smaller, minor products also displayed homology with TSG101, and their progressively smaller sizes were associated with an enlarging segment of deletion ( Figure 4 ).
Abnormal TSG101 mRNA determined by Northern blot analysis
To con®rm the presence of abnormal TSG101 transcripts and determine the relative abundance of these transcripts, Northern blot analysis was performed. Total RNA from ®ve SCLC cell lines and from two normal lung tissue samples were analysed. These SCLC samples were chosen to represent a spectrum of expression levels and to express slightly dierent versions of the truncated transcript. A hybridized band of about 1.5 kb could be seen for all samples corresponding to the full-sized TSG101 transcript, although it was extremely weak or absent in the SCLC cell lines H2171 and H2141 by Northern analysis ( Figure 5 ). Also seen from the SCLC cell lines was a band about 600 bp, corresponding well to the predicted size of the major aberrant TSG101 transcript detected as a 330 bp product by RT ± PCR. This band was clearly seen in three SCLC cell lines ( Figure 5 ). No abnormal band was observed in the normal tissues ( Figure 5 ).
Genomic DNA for TSG101 was not deleted or rearranged
To determine whether deletions or rearrangements of the TSG101 gene contributed to the abnormal transcripts observed in SCLC cell lines, Southern blot analysis was performed. Genomic DNA samples from Figure 2 RT ± PCR of SCLC cell lines for TSG101 using alternate primers. S1/AS1 was used in the top gel (wild-type transcript 1236 bp) and S1.1/AS1 in the lower gel (wild-type transcript 1228 bp). The wild-type and abnormal transcripts amplify with diering abundance in the dierent cell lines Figure 3 RT ± PCR of normal lung tissues for TSG101 cDNA. RT ± PCR of normal lung tissue for TSG101 cDNA, followed by Southern blot analysis, hybridizing with TSG101 cDNA-speci®c primer S1.1. Positive controls for shortened transcript: SCLC cell line H187 and human erythroblastic leukemia cell line K562 ten SCLC lines and four normal lymphoid tissue controls were digested with EcoRI and probed with full-length TSG101 cDNA. Six discrete bands were seen for each SCLC cell line as well as for normal lymphoid tissue samples (Figure 6a ). Each band presumably represents one or more speci®c exons since no EcoRI restriction site exists within the open reading frame of TSG101 cDNA. No band was altered or deleted in the ten SCLC cell lines, as well as the lymphoid tissue samples, suggesting no gross deletion or rearrangement of TSG101 in these SCLC cell lines.
Because the full-length cDNA probe could not distinguish between individual exons and also because the sizes of the bands together greatly exceed the predicted size (*15 kb) of the gene (Li et al., 1997) , it is possible that some of the visualized bands could represent parts of pseudogenes or sequence similarity within the genome. To further exclude the possible deletion or rearrangement of TSG101, we used a 506 bp probe speci®c for exon 1 of TSG101 to hybridize to the same Southern blot as described above. Since this probe overlaps 89 bp of the major truncated product, it should detect any corresponding genomic deletion or rearrangements as an abnormal band. However, probing with this exon 1-speci®c probe demonstrated only two bands for normal lymphoid tissue samples and SCLC cell lines; there was no abnormal band indicative of a genomic alteration (Figure 6b ). The appearance of two distinct bands hybridized by this small probe further supports that a pseudogene or a TSG101 homolog may exist.
Discussion
Is there evidence that TSG101 is a tumor suppressor gene in lung cancer? Work by Li and Cohen suggests that aberrations in expression of TSG101 may contribute to metastatic cell growth. Their tumor Figure 4 TSG101 gene structure reported by Li et al. (1997) and the shortened transcripts present in SCLC. Indicated is the sequence proposed to encode the critical coiled-coiled domain. Deletional breakpoints are depicted in four dierent aberrant TSG101 transcripts that were detected by RT ± PCR in SCLC lines Figure 5 Northern blot analysis for TSG101. A TSG101 cDNA probe applied to a Northern blot of total RNA from normal lung tissue and ®ve SCLC cell lines. In one SCLC cell line (H2171), the truncated transcript (*600 bp) far exceeds the wild-type (*1.5 kb). Relative densitometry readings are given for wildtype (®gures above lanes) and truncated bands (®gures below lanes). The sequence of the truncated transcripts for H2171, H187 and H146 are given in Figure 4 . The truncated transcripts for H2141 and H82 are not seen on a Northern blot at this exposure but are detected by RT ± PCR (Figures 1 and 2) xenograft model utilizing tsg101-knockout clones of NIH3T3 transformed cells resulted in an 80% incidence of spontaneous lung metastases (Li and Cohen, 1996) . We studied TSG101 for mutations in both SCLC and NSCLC cell lines which frequently show 11p allele loss. Our results show the vast majority of lung cancers express a wild-type transcript without mutations in the TSG101 open reading frame. Occasional SCLC lines either lacked the wild-type transcript or expressed it at very low levels. However, transcript analysis revealed that 89% of SCLC lines, but not NSCLC lines, also express a shortened transcript identical to one described by Li et al. (1997) in breast cancer.
Li and colleagues found abnormal TSG101 transcripts to be associated with genomic DNA deletion in primary breast tumors using a PCR-based assay (Li et al., 1997) . However, careful follow-up studies by Steiner et al. (1997) and Lee and Feinberg (1997) failed to ®nd any genomic deletions in breast cancer using Southern blot analysis. Similarly, our data demonstrate no genomic DNA deletion or rearrangement of TSG101 in SCLC cell lines expressing shortened transcripts by Southern blot analysis.
One explanation for coexpression of both normal and shortened transcripts in all SCLC cell lines could be the presence of a heterogenous collection of genomic deletions or rearrangements within each SCLC cell line or subpopulations within each cell line. Such deletions or rearrangements, however, would be expected on Southern blot analysis to result in abnormal bands of variable abundance. We did not detect any of these alterations on our Southern blot analysis ( Figure 6 ). It is possible that some genomic DNA abnormalities could be revealed by further extensive analysis using more restriction enzymes. Alternatively, intronic sequence alterations might contribute to the abnormal gene transcription. However, these possibilities are unlikely because: (1) one of the potential deletion breakpoints is located within exon 1 of the gene, while no aberrant bands could be detected by Southern blot analysis using an exon 1 speci®c probe; and (2) the common truncated transcript excludes more than three exons, which can not be explained by a mutation in only one of the introns, and multiple mutations in introns are highly unlikely to occur in all the SCLC cell lines tested. Thus our initial answer to the question of the role of Figure 6 (a) Southern blot analysis hybridizing TSG101 cDNA probe with genomic DNA from normal lymphoid tissue and SCLC cell lines. For each sample, all bands are present in equal ratios, suggesting that there are no exon deletions in the SCLC cell lines. The sum of the detected bands exceeds the reported length of the TSG101 gene raising the possibility of a homologous pseudogene being detected by the TSG101 cDNA probe. On the original ®lm there are two closely spaced bands at *23 kb to give a total of six bands. Similar to Steiner et al. (1997) . (b) Southern blot analysis hybridizing TSG101 exon 1 probe with genomic DNA from normal lymphoid tissue and SCLC cell lines. The exon 1 probe detects two bands, and this again suggests the possible existence of a pseudogene homologous to TSG101 or a dierent exon structure than that reported by Li et al. (1997) TSG101 in lung cancer is that it does not exhibit the usual characteristics expected of a tumor suppressor gene.
Our data suggest that probably all SCLC cell lines express an abnormal TSG101 transcript and that this phenomenon seems not to be a consequence of genomic DNA deletion or rearrangement. By default, aberrant splicing might be invoked to explain the normal expression of TSG101. Alternative splicing of mRNA regulates the production of a number of important biological molecules. Splice-editing of mRNA can regulate gene expression by preventing or promoting translation, or it can produce alternative protein products with disparate functions (Adams et al., 1996) . From the number of genes that are now known to be regulated by alternative splicing, it is clear that splicing regulation is an important adjunct to promoter-mediated regulation of gene expression (Rubinfeld et al., 1997; Roberts et al., 1996) . Internally deleted TSG101 transcripts may, therefore, represent variants which encode peptides of diering function. Lee and Feinberg (1997) indeed found the same shortened transcript in fetal tissue. However, the breakpoints of deletions in aberrant TSG101 transcripts were not located at intron/ exon boundaries of the gene. While intra-exon splicing has been documented in some natural systems (Kornblihtt et al., 1996; West et al., 1996) , this form of alternative splicing has been much less commonly described than inter-exon splicing, or`exon shuing'. Recent reports consistent with ours also suggest that abnormal TSG101 transcripts may be a phenomenon found in malignant tissues or cells (Steiner et al., 1997) .
Evidence is accumulating to indicate that abnormal transcription of critical genes such as tumor suppressor genes is frequent in human cancers (Lee and Feinberg, 1997; Sozzi et al., 1996; Sigalas et al., 1996) . The FHIT gene, located at 3p14, is a candidate tumor suppressor gene identi®ed by the positional cloning method. Abnormal transcripts were observed in 80% of SCLCs, 40% of NSCLCs, about 40% of HNSCCs and in several other tumor types (Sozzi et al., 1996; Mao et al., 1996; Fong et al., 1997) . These alterations include deletions of one or more exons and insertion of variously sized intron sequences at the RNA level. The abnormal FHIT gene transcripts were not always correlated with deletions at the genomic DNA level (Druck et al., 1997; Fong et al., 1997) . While most SCLC lines express both shortened TSG101 and aberrantly spliced FHIT transcripts, we did observe two SCLCs that did not express the shortened TSG101 transcript but did express abnormal FHIT transcripts . This would suggest that there is not an absolute correlation for such aberrant transcript production.
The mdm2 oncogene encodes a 90 kD nuclear phosphoprotein that binds to and inactivates the p53 tumor suppressor protein. A recent study showed that abnormally spliced mdm2 gene transcripts are frequent in a range of human cancers but absent in normal tissues (Liang et al., 1997) . In at least one of these abnormal transcripts, the deletion break points were not located at intron/exon boundaries (Liang et al., 1997) . Of the ®ve abnormal transcripts described, most lacked the p53 binding domain sequences, and all of them had tumorigenic properties (Liang et al., 1997) . Furthermore, a higher frequency of splice variants of mdm2 was observed in late-stage and high-grade tumors (Sigalas et al., 1996) . These data suggest that dysregulation of RNA splicing may contribute to instability in human cancers, disrupting critical tumor suppressor genes or creating abnormal gene products that have oncogenic properties.
Materials and methods
Cell lines and cell culture
Nearly all of the lung cancer lines have been deposited in the American Type Culture Collection (ATCC) (Rockville, MD). The SCLC cell lines used in this study were: NCI-H69, -H82, -H128, -H146, -H187, -H196, -H209, -H211, -H220, -H249, -H289, -H250, -H345, -H378, -H524, -H526, -H711, -H735, -H738, -H740, -H841, -H847, -H865, -H889, -H1045, -H1092, -H1105, -H1184, -H1304, -H1339, -H1450, -H1514, -H1618, -H1672, -H1688, -H1926, -H1963, -H2107, -H2108, -H2141, -H2171, -H2227, HCC970 and DMS 79. The NSCLC cell lines were: NCI -H23, -H157, -H358, -H441, -H460, -H727, -H838, -H920, -H1155, -H1299, -H1437, -H1466, -H1573, -H1666, -H1693, -H1770, -H1792, -H1819, -H1993, -H2009, -H2077, -H2087, -H2122, -H2347, -H2452, -H2882, HCC44, HCC78, HCC95, HCC193, HCC515, HCC827 and HCC1171. Lines pre®xed NCI-H were established by us (JDM and AFG) at the NCI, while those pre®xed HCC (Hamon Cancer Center) were established by us (JDM and AFG) at UT Southwestern. SCLC and NSCLC cell lines were grown in RPMI 1640 with 10% fetal bovine serum.
The tumor cell lines are all distinct from one another by virtue of karyotype and DNA ®ngerprinting analyses, with several polymorphic probes, and by a variety of other studies such as p53 and ras mutation analyses. The NCI lines were derived over a 15 year period and had undergone 50 ± 100 passages at the time of analysis, while the HCC lines have been established in the past 5 years and have undergone 10 ± 40 passages. Allelotyping of the 11p marker D11S740 revealed loss of heterozygosity in 5/10 SCLC and 7/14 NSCLC lines where normal DNA was available for comparison (Virmani et al., 1998) .
HNSCC cell lines were grown in DMEM with 10% fetal bovine serum and were kind gifts from Dr Thomas E Carey, University of Michigan, Ann Arbor, MI (UMSCC10B, UMSCC11B, UMSCC14B, UMSCC17B and 38); Dr Peter G Sacks, Memorial Sloan Kettering Institute, New York, NY (183A and 886Ln); Dr Alfonse Balm, The Netherlands Cancer Institute, Amsterdam, Netherlands (Tr146); and Dr Michael Reiss, Yale University, New Haven, CT (SqCC/Y1). Normal lung tissue specimens were obtained from surgical biopsy or resection specimens and stored at 7808C.
DNA isolation and Southern blot analysis
Genomic DNA was isolated from SCLC cell line cultures by proteinase K digestion (0.1 mg/ml) overnight at 508C followed by phenol/chloroform extraction and ethanol precipitation. Equal quantities of DNA from each sample were digested with EcoRI (10 U/mg) overnight at 378C. Five mg of digested genomic DNA from each sample was electrophoresed on a 0.8% agarose gel. DNA was transferred to a Hybond-N nylon membrane (Amersham Life Science, Inc., Arlington Heights, IL) then ®xed by UV cross-linking. Following prehybridization at 658C in Rapid-Hyb buer (Amersham Life Science, Inc.) for 1 h, the membrane was hybridized overnight at 658C with TSG101 cDNA probes. Probes were synthesized by PCR ampli®cation of a 1236 bp (containing the complete open reading frame sequence) or a 506 bp product of the TSG101 exon 1 using primer pair S1/AS1 or S1/AS3 respectively and labeled with [g 32 P]dGTP using a nick translation labeling kit (Boehringer Mannheim, Mannheim, Germany). The membrane was washed sequentially with 16SSC/0.1% SDS (658C for 30 min), then 0.16SSC/0.1% SDS (658C for 30 min) and exposed to autoradiography ®lm for 2 ± 5 days. For Southern blots of PCR products the membrane was prehybridized in 66SSC, 56Denhardt's solution, 0.1% SDS and 100 mg/ml of salmon sperm DNA for 1 h at 688C. Then the primer S1.1 was end-labeled with [g 32 P]dATP and used as an oligo-probe, hybridizing with the membrane for 1 h at 608C in 66SSC, 56Denhardt's solution, 0.1% SDS and 100 mg/ml of salmon sperm DNA also containing 0.1 M EDTA. The membrane was washed twice in 26SSC and 0.1% SDS buer at room temperature for 5 min followed by a stringent wash in 36SSC and 0.1% SDS at 628C for 30 min and exposed to autoradiography ®lm for 2 days.
RNA isolation and Northern blot analysis
For total RNA extraction from cell lines, the cell pellets were quickly suspended in RNAzol B solution (Biotecx Laboratories, Inc., Houston, TX) to lyse the cells. For fresh tissue samples, 50 ± 100 mg of tissues were mechanically homogenized in 1 ml RNAzol B solution (Biotecx Laboratories, Inc.). Total RNA was extracted following the manufacturer's protocol. Approximately 20 mg of total RNA per sample was denatured, electrophoresed, and transferred to a Hybond-N nylon membrane (Amersham Life Science, Inc.). The membrane was ®xed by UV crosslinking, prehybridized at 658C in Rapid-Hyb solution (Amersham Life Science, Inc.) for 1 h and hybridized overnight at 658C with the full-length TSG101 cDNA probe described above. The membrane was then washed sequentially with 16SSC/0.1% SDS (658C for 30 min), then 0.16SSC/0.1% SDS (658C for 30 min) and exposed to autoradiography ®lm for 3 days.
Reverse transcription and PCR analysis
Random-primed or oligo dT-primed cDNAs were prepared from total RNA (3 mg) using SuperScript II RNAse H 7 reverse transcriptase (Gibco ± BRL, Gaithersburg, MD) according to the manufacturer's protocol. From GenBank's published sequence for human TSG101 (GenBank U82130) two primer sets were designed to amplify the TSG101 ORF: S1 (bp 65±82): 5'GGGAAGGGA-GTCGCCAGG-3'/AS1 (bp 1281 ± 1300): 5'-TTAAGAA-GAGCTCAACCTCC-3' and S1.1 (bp 73 ± 93): 5'-AGTC-GCCAGGCGGCCGTCATG-3'/AS1. The primers S1 and AS3 (bp 553 ± 570): 5'-ATTTGGTGGCCCCGTTGC-3' were selected to amplify exon 1 of the TSG101 gene. One ml of 1 : 10 diluted cDNAs were ampli®ed in RT ± PCR reactions containing 0 ± 3% dimethylsulfoxide, 200 mM each dNTP, 1.5 mM MgCl 2 , 0.4 mM PCR primers and 2.5 units of Taq DNA polymerase (Gibco ± BRL). Reactions were carried out in a Hybaid thermocycler (Omnigene, Woodbridge, NJ) for 35 cycles of 958C for 30 s, 60 ± 628C for 60 s and 728C for 60 s, followed by a 5 min extension at 728C. For PCR ampli®cation of genomic DNA the primer pair S1/AS1 was used with Taq and recombinant Pfu DNA polymerases from the Taq Plus Long kit (Stratagene, La Jolla, CA) according to the manufacturer's speci®cations.
Sequencing of PCR products
Following PCR, bands of interest were excised from a 1.5% agarose gel and puri®ed using Qiaquick resin columns (Qiagen, Chatsworth, CA). Between 10 ± 15 ng of DNA per sample was used for each direct sequencing reaction containing a primer labeled with g 33 P-dATP and ampli®ed by PCR for 30 cycles using the AmpliCycle sequencing kit (Perkin-Elmer, Blanchburg, NJ) according
